Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Indian buyer for German generics firm?
February 13, 2006
| A version of this story appeared in
Volume 84, Issue 7
India's financial press is reporting that either Ranbaxy Laboratories or Dr. Reddy's Laboratories will pay as much as $600 million to buy Betapharm, Germany's fourth largest generic drug producer. Betapharm was acquired in March 2004 for $360 million by 3i, a U.K.-based venture-capital firm. 3i, which put Betapharm up for sale in November, says Betapharm has "sustained above-average growth in a consolidating market." A Ranbaxy official tells C&EN that "Ranbaxy is actively looking at acquisition opportunities in the U.S., Europe, and India." At Dr. Reddy's, a spokesman says "time will tell" whether any deal takes place.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter